Pancancer Analyses Reveal Genomics and Clinical Characteristics of the SETDB1 in Human Tumors

Figure 9

Methylation and protein phosphorylation analysis. (a–l) The differential DNA methylation level of SETDB1 promoter in twelve tumor types. (a) UCEC, (b) TGCT, (c) READ, (d) PRAD, (e) LUSC, (f) LUAD, (g) LIHC, (h) HNSC, (i) ESCA, (j) COAD, (k) BRCA, and (l) BLCA. (m–s) The prognosis value of single CpG (cg10444928) of SETDB1 in seven tumor types. (m) UCS, (n) UVM, (o) MESO, (p) KIRC, (q) KIRP, (r) LGG, and (s) CESC. (t) Phosphorylation site of SETDB1 protein. (u–z) The differential protein level of SETDB1 in S1006 site in six tumor types. (u) Breast cancer, (v) glioblastoma multiforme, (w) pancreatic adenocarcinoma, (x) head and neck squamous carcinoma, (y) lung adenocarcinoma, and (z) clear cell RCC.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)

(m)

(n)

(o)

(p)

(q)

(r)

(s)

(t)

(u)

(v)

(w)

(x)

(y)

(z)